Cynapsus Therapeutics Inc. (CYNA): OrbiMed Advisors Adds To Its Stake

Page 2 of 7 – SEC Filing

CUSIP No. 23257Y859

SCHEDULE 13G

Page 2 of 7 Pages

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) OrbiMed Capital GP V LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 1,620,325
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 1,620,325
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,620,325
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)			o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 13.2%(1)
12	TYPE OF REPORTING PERSON (See Instructions) OO

(1) This percentage is calculated based upon 12,316,441 shares of the Issuer’s Common Stock (“Shares”) outstanding, as set forth in the Issuer’s Form 10-Q, dated May 10, 2016, filed with the Securities and Exchange Commission on May 11, 2016.